These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27812962)

  • 21. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
    Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
    Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Scheen AJ
    Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton RJ
    Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
    Scheen AJ; Wallemacq C; Jandrain B; Ernest P
    Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
    Abdul-Ghani M; Del Prato S; Chilton R; DeFronzo RA
    Diabetes Care; 2016 May; 39(5):717-25. PubMed ID: 27208375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial].
    Okamura T; Koiwai K
    Nihon Yakurigaku Zasshi; 2016; 148(5):282. PubMed ID: 27803444
    [No Abstract]   [Full Text] [Related]  

  • 39. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
    Jørgensen NB; Pedersen J; Vaag AA
    J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
    [No Abstract]   [Full Text] [Related]  

  • 40. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Mudaliar S; Alloju S; Henry RR
    Diabetes Care; 2016 Jul; 39(7):1115-22. PubMed ID: 27289124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.